Clinical trials: Patent Ductus Arteriosus in Preterm Infants
Bronchopulmonary Dysplasia
Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia
Urinary ascorbyl peroxide level in the first week of life will be a good predictor of Bronchopulmonary dysplasia (BPD) in preterm infants less than 33 weeks of gestation.
- Trial name
- NCT01439295
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- St. Justine's Hospital
Persistent Ductus Arteriosus, Complication of Prematurity
The Preterm Infants' Paracetamol Study
Present randomized, controlled, double-blind trial investigates the efficacy and safety of early (<24 h) intravenous paracetamol therapy for pain medication in very small premature infants.
- Conditions
- Persistent Ductus Arteriosus, Complication of Prematurity, Pain or Discomfort in Intensive Care of Preterm Infants
- Trial name
- PreParaS (NCT01938261)
- Testing
- paracetamol, 0.45 % saline solution
- Where
- Finland
- Volunteers
- 120 people
- Sponsor
- University of Oulu
Patent Ductus Arteriosus
Aminoglycosides and Duct
The aim of the study is to assess the effect of aminoglycoside treatment on ductal closure in preterms
- Trial name
- NCT04415554
- Testing
- echocardiography
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Carmel Medical Center
Patent Ductus Arteriosus, Surgery
Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
The primary goal of the trial is to compare two different Patent Ductus Arteriosus (PDA) treatment approaches: 1) an "early treatment" approach or 2) a "conservative" approach.
- Conditions
- Patent Ductus Arteriosus, Surgery, Necrotizing Enterocolitis, Intestinal Perforation
- Trial name
- PDA:TOLERATE (NCT01958320)
- Testing
- pharmacologic treatment of the PDA, no pharmacologic treatment of the PDA, NSAID
- Where
- 18 sites in United States, Sweden and 2 more
- Volunteers
- 202 people
- Sponsor
- University of California, San Francisco
Patent Ductus Arteriosus
IV Acetaminophen and Patent Ductus Arteriosus
This is a randomized controlled trial to evaluate the efficacy of IV acetaminophen versus IV ibuprofen in closing a hemodynamically significant patent ductus arteriosus in preterm infants.
- Trial name
- NCT03008876
- Testing
- Acetaminophen, Ibuprofen
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Albany Medical College
Patency of the Ductus Arteriosus, Acetaminophen
Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen
TREOCAPA is a Phase II/III European Multicentre study concerning the prophylactic treatment by Acetaminophen of extremely preterm infant during the first five days after birth.
- Conditions
- Patency of the Ductus Arteriosus, Acetaminophen, Extreme Prematurity
- Trial name
- TREOCAPA (NCT04459117)
- Testing
- Acetaminophen, NACL 0.9%
- Where
- 36 sites in Belgium, Denmark and 10 more
- Volunteers
- 804 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Patent Ductus Arteriosus
Patent Ductus Arteriosus and Splanchnic Oxygenation at First Feed
Patent ductus arteriosus (PDA) is common in preterm infants. In the presence of a large PDA, significant systemic to pulmonary shunting occurs, which may results in pulmonary hyperperfusion and systemic hypoperfusion.
- Trial name
- NCT03723889
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Patent Ductus Arteriosus After Premature Birth
Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT
Background: Among preterm infants, those born at a gestational age less than 26 weeks are considered the most vulnerable with a high risk of short- and long-term health problems that include chronic lung disease, brain bleeds…
- Trial name
- SMART-PDA (NCT05011149)
- Testing
- Ibuprofen
- Where
- 9 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- IWK Health Centre
Patent Ductus Arteriosus
PDA Post NICU Discharge
The purpose of this study is to track post-discharge outcomes on prematurely born infants who are discharged from the NICU with a patent ductus arteriosus (PDA).
- Trial name
- PDA (NCT02750228)
- Where
- 16 sites in United States
- Volunteers
- 208 people
- Sponsor
- Pediatrix
Patent Ductus Arteriosus, Infant, Premature
Ibuprofen vs Expectant Management for hsPDA in Preterm Infants: Retrospective Cohort
This retrospective cohort study compares ibuprofen treatment versus expectant management for hemodynamically significant patent ductus arteriosus (hsPDA) in preterm infants.
- Trial name
- IMPACT-PDA (NCT07533721)
- Testing
- Ibuprofen
- Where
- China
- Volunteers
- 541 people
- Sponsor
- Shengjing Hospital
Ductus Arteriosus, Patent
Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies
Premature babies are affected by a condition known as "patent ductus arteriosus" in which the ductus arteriosus (a normal structure) fails to close after birth as it should.
- Trial name
- NCT00725647
- Volunteers
- 102 people
- Sponsor
- St George's, University of London
Patent Ductus Arteriosus
Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants
This is a retrospective chart review to look at the timing of using indomethacin and ibuprofen for PDA closure for infants admitted into the NICU of the University of Utah Hospital from 1/2007-8/2008.
- Trial name
- NCT00795990
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- University of Utah
Ductus Arteriosus, Patent
Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious
Patent ductus arterious(PDA)is frequently seen and potentially pathologic in preterm infants. Near-infrared spectroscopy is a simple bedside tool to analyse the changes in the renal and splanchnic tissue oxygenation index and…
- Trial name
- NCT01251939
- Testing
- Near-infrared spectroscopy (NIRS)
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
Left Ventricular Hypertrophy
Postnatal Steroids Effects on Cardiac Function in Extremely Preterm
Hypothesis/Study question In infants born at less than 29 weeks of estimated gestational age, what are the effects of dexamethasone use on cardiac structure/performance and lung water content? Study objectives To measure effects…
- Trial name
- SPEC (NCT04644094)
- Testing
- Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Patent Ductus Arteriosus
Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA
The purpose of this study is to determine the safety and effectiveness of ibuprofen l-lysine iv in premature infants in the early treatment of Patent Ductus Arteriosus.
- Trial name
- NCT00440804
- Testing
- ibuprofen l-lysine iv solution (NeoProfen (R) )
- Sponsor
- Farmacon
Patent Ductus Arteriosus in Preterm Infants
Radiological Markers for PDA Management in Preterm Infants
The aim of this Randomized controlled trial is to determine whether Echo with Organ Doppler-guided management strategy for hemodynamically significant patent ductus arteriosus (hsPDA) improves the short-term outcomes compared…
- Trial name
- NCT07812064
- Testing
- Organ doppler, Echocardiography
- Volunteers
- 88 people
- Sponsor
- Assiut University
Infant, Premature, Congenital Heart Disease
Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
Patent ductus arteriosus (PDA) is a common problem in the neonatal intensive care unit and can be secondary to prematurity or congenital heart disease (CHD).
- Conditions
- Infant, Premature, Congenital Heart Disease, Patent Ductus Arteriosus, Necrotizing Enterocolitis
- Trial name
- NCT03551600
- Testing
- Near-infrared spectroscopy (NIRS)
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of Utah
Patent Ductus Arteriosus
Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure
Using cerebral and renal near infrared spectroscopy monitoring to determine PDA closure in preterm infants after completing medical treatment for a hemodynamically significant PDA.
- Trial name
- NCT03026192
- Testing
- near infrared spectroscopy
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Albany Medical College
Patent Ductus Arteriosus, Extreme Prematurity
Canadian National PDA Treatment Study
Patent ductus arteriosus (PDA) is the most common cardiovascular problem that develops in preterm infants. Persistent PDA may result in higher rates of death, chronic lung disease (CLD), pulmonary hemorrhage, necrotizing…
- Trial name
- CANRxPDA (NCT04347720)
- Testing
- Indomethacin, Ibuprofen, Acetaminophen
- Where
- 22 sites in Canada
- Volunteers
- 1,663 people
- Sponsor
- IWK Health Centre
Bronchopulmonary Dysplasia, Patent Ductus Arteriosus
MISA to NRDS：a Multicenter Study in China
BACKGROUND Treatment of neonatal respiratory distress syndrome with exogenous surfactant and mechanical ventilation made millions of preterm infants survived in neonatal intensive care unit (NICU).
- Conditions
- Bronchopulmonary Dysplasia, Patent Ductus Arteriosus, Intraventricular Hemorrhage, Necrotizing Enterocolitis
- Trial name
- NCT04077333
- Testing
- Minimal Invasive surfactant administration
- Where
- China
- Volunteers
- 237 people
- Sponsor
- Peking University Third Hospital